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etter to the editor
etection  of  cytogenetic  abnormalities  in  mature
-cell neoplasms:  the value of cultures  with
ifferent mitogens
ature B-cell neoplasms are a common group of
ematological malignancies in Western counties with
he most prevalent being chronic lymphocytic leukemia
CLL). Clonal cytogenetic abnormalities are observed in only
0% of the CLL cases studied by conventional cytogenetic
echniques (karyotyping) and up to 80% of the cases studied
sing the ﬂuorescence in situ hybridization (FISH) technique
ith probes to investigate 6q21,11q22-23 (ATM), 13q14.3
nd 17p13 (P53) deletions and for trisomy 12. Cytogenetic
bnormalities are associated with prognosis; deletion of 13q
s associated with the best prognosis and deletion of 17p
ith the worst. Despite the greater sensitivity of FISH, it is
xpensive and does not detect abnormalities other than those
nvestigated. Conventional cytogenetic studies in CLLs are
ften disappointing because no metaphases or only normal
etaphases are obtained.
It is very important to send a sample containing the neo-
lastic cells to be analyzed to the lab for the cytogenetic
tudy. In lymphoid malignancies this sample can be from a
ymph node, the spleen, or other affected tissue, including
one marrow and peripheral blood when leukemized. The use
f mitogenic agents to stimulate B-cells in cultures has been
seful. The potent tumor promoter 12-myristate 13-acetate
TPA) has given the highest clone detection rate in the cyto-
enetic laboratory. Moreover, culturing is performed without
ny other stimulating agent. In the late 1990s, the use of
ew cytogenetic protocols with different mitogens such as the
pG-oligonucleotide DSP30 plus interleukin-2 (IL-2) improved
he detection of clonal abnormalities in up to 80% in CLL.
SP30 also induces the IL-2 alpha receptor (possibly via CD25)
n CLL cells thereby allowing IL-2 to generate a co-stimulatory
ffect.
The combination of these different mitogens was described
y three different groups.
A study by Dicker et al. in Germany, with 132 CLL samples,
howed successful cultures in 125 cases, 81% of which showed
lonal abnormalities with the most prevalent being del6q,
el11q, +12, del13q, del17p and the 14q32 rearrangement.1In a Brazilian study conducted by Morato et al., clonal cyto-
genetic abnormalities were detected in 80% of the 35 cases
studied, showing recurring abnormalities (del6q, del11q, +12,
del13q, −17/del17q, 14q32 rearrangement) as well as many
others (+4, +5, +8, +11, +15, del12p13, +18, +19, +21, and bal-
anced translocations involving different chromosomes).2
A study by Wren  et al. in Australia failed to reproduce these
data. Forty-ﬁve samples of CLL were submitted to cultures
stimulated with TPA, DSP30 together with IL-2 and combined
TPA and DSP30+IL-2. The rate of detection of chromosomal
abnormalities was higher, signiﬁcance, in the cultures with
TPA+DSP30+IL-2 (52.9%) than with TPA (45.8%) or DSP30+IL-2
(29.2%). Additionally, there was a greater success in the culture
with TPA (100%) than with DSP30+IL-2 (72.7%) and the mitotic
index and resolution of bands were also more  successful in
the TPA culture.3
In view of these conﬂicting data in the literature, we
compared the detection of clonal abnormalities using three
different cultures mentioned in the literature: without stim-
ulating agent, TPA and DSP30+IL-2 (200 U/mL) and another
with a higher concentration of IL-2 (DSP30+IL-2 [400 U/mL])
using 16 samples of mature B-cell neoplasms (11 were CLL).
At least ten metaphases from each culture were analyzed in
an Ikaros karyotyping System (MetaSystems) by two  analysts,
and the karyotype was described according to the Interna-
tional System for Human Cytogenetic Nomenclature (ISCN)
2013. Table 1 shows the results in cases with clonal abnormal-
ities.
The incidence of clonal abnormalities in mature B-cell
neoplasms in this study was 50%, with trisomy 12 being
the most common abnormality. The culture with DSP30+IL-
2 (400 U/mL) showed a lower failure rate than that with
DSP30+IL-2 (200 U/mL). There was no detection of new clonal
abnormalities in the DSP30+IL-2 culture compared to TPA.
The culture with the oligonucleotide increased reagent costs
of karyotyping by 3% with a lower resolution in G-banding;
however, it was able to detect a higher percentage of cells
with aberrant clones. Perhaps the combination of the three
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Table 1 – Cytogenetic abnormalities and percentage of abnormal clones in cultures without stimulant, with TPA, DSP30
together with IL-2 (200 U/mL) and DSP30 together with IL-2 (400 U/mL).
Cytogenetic abnormali-
ties/neoplasms
Culture  without
stimulant (24 and 48 h)
(%)
Culture with TPA
(72 h)
(%)
Culture with DSP30 and
IL-2 (200 U/mL) (72 h)
(%)
Culture with
DSP30 and IL-2
(400 U/mL) (72 h)
(%)
−20 (CLL) Absence of metaphases 20.0 Absence of metaphases –
+12 (CLL) 0 60.0 Absence of metaphases –
+12, del(14)(q22q24) (B
cell neoplasms)
83.3  85.7 Absence of metaphases –
XXY, der(1)t(1;?)(p13;?),
der(3)t(3;?)(p13;?),
del(6)(q21)x2, −8, −9,
−10, +13,
add(19)(p13.3), −22 (B
cell neoplasms)
30.0  20.0 – 80.0
+12/del(20)(q11.2) (CLL) 50.0/0 55.5/22.2 – 80.0/0
t(1;13)(q?25;q14),
add(17)(p12), −18
(CLL)
10.0  30.0 – 60.0
i(17)(q10) (CLL) 0 20.0 – 50.0
+1, del(1)(p34) (B cell
neoplasms)
Absence of metaphases 10.0 – 40.0
n-2.
r
1
2
3TPA: 12-myristate 13-acetate; oligonucleotide: DSP30; IL-2: interleuki
mitogens may be an effective approach to karyotype mature
B-cell neoplasms as suggested by the Australian group.
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